Login Register Cart 0
Generic placeholder image

Drug Delivery Letters

Editor-in-Chief

ISSN (Print): 2210-3031
ISSN (Online): 2210-304X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Current Remedial Strategies for the Treatment of Rheumatoid Arthritis through the Oral Route with Janus Kinase Inhibitors

Author(s): Pooja Mathur, Ravinder Verma, Manish Kumar, Vikas Jhawat, Rohit Dutt and Shailendra Bhatt*

Volume 13, Issue 1, 2023

Published on: 09 December, 2022

Page: [13 - 23] Pages: 11

DOI: 10.2174/2210303113666221103104829

Price: $65

conference banner
Abstract

Rheumatoid arthritis (RA) is a well-known chronic inflammatory disease that results in articular degradation, comorbidities, and body part functional loss. In the last two decades, the development of effective biologics and small compounds, such as Janus kinase inhibitors (Jakinibs), has significantly improved clinical outcomes. Low-molecular-weight chemicals known as jakinibs are currently used for effective treatment of RA. Jakinibs are a new class of drugs being developed to treat RA, and several of them are now in different phases of clinical trials to establish their safety and efficacy in humans. Jakinibs can be very different in their selectivity against JAK inhibitors.

For an efficient therapy of RA, it is critical to fully comprehend the properties of JAK inhibitors as well as their mechanism of action. Tofacitinib, Baricitinib, Upadacitinib, Peficitinib, Filgotinib, Decernotinib, Itacitinib, Ruxolitinib, and PF-06651600 are a few selective orally active Jakinibs that have entered clinical trials to treat RA. This review aims to elaborate on Jakinibs for the treatment of Rheumatoid Arthritis (RH), including their mechanism of action (MOA), efficacy and safety profiles, clinical trials of adverse effects (AEs) associated with Jakinibs and combination therapy with other DMARDs.

« Previous Next »
Graphical Abstract

[1]
Tanaka, Y. A review of upadacitinib in rheumatoid arthritis. Mod. Rheumatol., 2020, 30(5), 779-787.
[http://dx.doi.org/10.1080/14397595.2020.1782049] [PMID: 32530345]
[2]
Kang, E.H.; Liao, K.P.; Kim, S.C. Cardiovascular safety of biologics and JAK inhibitors in patients with rheumatoid arthritis. Curr. Rheumatol. Rep., 2018, 20(7), 42.
[http://dx.doi.org/10.1007/s11926-018-0752-2] [PMID: 29846814]
[3]
Vaddi, K.; Luchi, M. JAK inhibition for the treatment of rheumatoid arthritis: A new era in oral DMARD therapy. Expert Opin. Investig. Drugs, 2012, 21(7), 961-973.
[http://dx.doi.org/10.1517/13543784.2012.690029] [PMID: 22612502]
[4]
Kawalec, P.; Mikrut, A. Wiśniewska, N.; Pilc, A. The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: A systematic review and meta-analysis. Clin. Rheumatol., 2013, 32(10), 1415-1424.
[http://dx.doi.org/10.1007/s10067-013-2329-9] [PMID: 23877486]
[5]
Messemaker, T.C.; Huizinga, T.W.; Kurreeman, F. Immunogenetics of rheumatoid arthritis: Understanding functional implications. J. Autoimmun., 2015, 64, 74-81.
[http://dx.doi.org/10.1016/j.jaut.2015.07.007] [PMID: 26215034]
[6]
Taylor, P.C. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Rheumatology, 2019, 58(1), i17-i26.
[http://dx.doi.org/10.1093/rheumatology/key225] [PMID: 30806707]
[7]
Jang, S.; Kwon, E.J.; Lee, J.J. Rheumatoid arthritis: Pathogenic roles of diverse immune cells. Int. J. Mol. Sci., 2022, 23(2), 905.
[http://dx.doi.org/10.3390/ijms23020905] [PMID: 35055087]
[8]
Kotyla, P.J. Are Janus kinase inhibitors superior over classic biologic agents in RA patients? BioMed Res. Int., 2018, 2018, 1-9.
[http://dx.doi.org/10.1155/2018/7492904] [PMID: 29862290]
[9]
Emery, P.; Pope, J.E.; Kruger, K.; Lippe, R.; DeMasi, R.; Lula, S.; Kola, B. Efficacy of monotherapy with biologics and JAK inhibitors for the treatment of rheumatoid arthritis: A systematic review. Adv. Ther., 2018, 35(10), 1535-1563.
[http://dx.doi.org/10.1007/s12325-018-0757-2] [PMID: 30128641]
[10]
Fitton, J.; Melville, A.R.; Emery, P.; Nam, J.L.; Buch, M.H. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway. Rheumatology, 2021, 60(9), 4048-4054.
[http://dx.doi.org/10.1093/rheumatology/keaa858] [PMID: 33331938]
[11]
Angelini, J.; Talotta, R.; Roncato, R.; Fornasier, G.; Barbiero, G.; Dal Cin, L.; Brancati, S.; Scaglione, F. JAK-inhibitors for the treatment of rheumatoid arthritis: A focus on the present and an outlook on the future. Biomolecules, 2020, 10(7), 1002.
[http://dx.doi.org/10.3390/biom10071002] [PMID: 32635659]
[12]
Mogul, A.; Corsi, K.; McAuliffe, L. Baricitinib: The second FDA-approved JAK inhibitor for the treatment of rheumatoid arthritis. Ann. Pharmacother., 2019, 53(9), 947-953.
[http://dx.doi.org/10.1177/1060028019839650] [PMID: 30907116]
[13]
Morinobu, A. JAK inhibitors for the treatment of rheumatoid arthritis. Immunol. Med., 2020, 43(4), 148-155.
[http://dx.doi.org/10.1080/25785826.2020.1770948] [PMID: 32501149]
[14]
Cai, J.; Hosmane, N.S.; Takagaki, M.; Zhu, Y. Synthesis, molecular docking, and in vitro boron neutron capture therapy assay of carboranyl sinomenine. Molecules, 2020, 25(20), 4697.
[http://dx.doi.org/10.3390/molecules25204697] [PMID: 33066470]
[15]
Keeling, S.; Maksymowych, W.P. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: A critical review of clinical trials. Expert Rev. Clin. Immunol., 2021, 17(7), 701-715.
[http://dx.doi.org/10.1080/1744666X.2021.1925541] [PMID: 33944642]
[16]
You, H.; Xu, D.; Zhao, J.; Li, J.; Wang, Q.; Tian, X.; Li, M.; Zeng, X. JAK inhibitors: Prospects in connective tissue diseases. Clin. Rev. Allergy Immunol., 2020, 59(3), 334-351.
[http://dx.doi.org/10.1007/s12016-020-08786-6] [PMID: 32222877]
[17]
Kumar, P.; Banik, S. Pharmacotherapy options in rheumatoid arthritis. Clin. Med. Insights Arthritis Musculoskelet. Disord., 2013, 6, CMAMD-S5558.
[http://dx.doi.org/10.4137/CMAMD.S5558] [PMID: 23997576]
[18]
Zerbini, C.A.F.; Lomonte, A.B.V. Tofacitinib for the treatment of rheumatoid arthritis. Expert Rev. Clin. Immunol., 2012, 8(4), 319-331.
[http://dx.doi.org/10.1586/eci.12.19] [PMID: 22607178]
[19]
Harigai, M.; Honda, S. Selectivity of Janus kinase inhibitors in rheumatoid arthritis and other immune-mediated inflammatory diseases: Is expectation the root of all headache? Drugs, 2020, 80(12), 1183-1201.
[http://dx.doi.org/10.1007/s40265-020-01349-1] [PMID: 32681420]
[20]
Singh, S.; Singh, S. JAK-STAT inhibitors: Immersing therapeutic approach for management of rheumatoid arthritis. Int. Immunopharmacol., 2020, 86106731
[http://dx.doi.org/10.1016/j.intimp.2020.106731] [PMID: 32590315]
[21]
Dowty, M.E.; Lin, T.H.; Jesson, M.I.; Hegen, M.; Martin, D.A.; Katkade, V.; Menon, S.; Telliez, J.B. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. Pharmacol. Res. Perspect., 2019, 7(6)e00537
[http://dx.doi.org/10.1002/prp2.537] [PMID: 31832202]
[22]
Harrington, R.; Al Nokhatha, S.A.; Conway, R. JAK inhibitors in rheumatoid arthritis: An evidence-based review on the emerging clinical data. J. Inflamm. Res., 2020, 13, 519-531.
[http://dx.doi.org/10.2147/JIR.S219586] [PMID: 32982367]
[23]
Ni, H.; Moe, S.; Myint, K.T.; Htet, A. Oral janus kinase inhibitor for the treatment of rheumatoid arthritis. Tofacitinib. ISRN Rheumatol., 2013, 2013, 1-9.
[http://dx.doi.org/10.1155/2013/357904] [PMID: 23970975]
[24]
Atzeni, F.; Talotta, R.; Nucera, V.; Marino, F.; Gerratana, E.; Sangari, D.; Masala, I.F.; Sarzi-Puttini, P. Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors. Expert Rev. Clin. Immunol., 2018, 14(11), 945-956.
[http://dx.doi.org/10.1080/1744666X.2018.1504678] [PMID: 30058434]
[25]
Schwartz, D.M.; Kanno, Y.; Villarino, A.; Ward, M.; Gadina, M.; O’Shea, J.J. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat. Rev. Drug Discov., 2017, 16(12), 843-862.
[http://dx.doi.org/10.1038/nrd.2017.201] [PMID: 29104284]
[26]
O’Shea, J.J.; Kontzias, A.; Yamaoka, K.; Tanaka, Y.; Laurence, A. Janus kinase inhibitors in autoimmune diseases. Ann. Rheum. Dis., 2013, 72(S2), ii111-ii115.
[http://dx.doi.org/10.1136/annrheumdis-2012-202576] [PMID: 23532440]
[27]
Kotyla, P.J.; Islam, M.A.; Engelmann, M. Clinical aspects of janus kinase (jak) inhibitors in the cardiovascular system in patients with rheumatoid arthritis. Int. J. Mol. Sci., 2020, 21(19), 7390.
[http://dx.doi.org/10.3390/ijms21197390] [PMID: 33036382]
[28]
Berekmeri, A.; Mahmood, F.; Wittmann, M.; Helliwell, P. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev. Clin. Immunol., 2018, 14(9), 719-730.
[http://dx.doi.org/10.1080/1744666X.2018.1512404] [PMID: 30118353]
[29]
Nakayamada, S.; Kubo, S.; Iwata, S.; Tanaka, Y. Chemical JAK inhibitors for the treatment of rheumatoid arthritis. Expert Opin. Pharmacother., 2016, 17(16), 2215-2225.
[http://dx.doi.org/10.1080/14656566.2016.1241237] [PMID: 27690665]
[30]
MacFarlane, L.A.; Todd, D.J. Kinase inhibitors: The next generation of therapies in the treatment of rheumatoid arthritis. Int. J. Rheum. Dis., 2014, 17(4), 359-368.
[http://dx.doi.org/10.1111/1756-185X.12293] [PMID: 24460872]
[31]
Fleischmann, R.; Kremer, J.; Tanaka, Y.; Gruben, D.; Kanik, K.; Koncz, T.; Krishnaswami, S.; Wallenstein, G.; Wilkinson, B.; Zwillich, S.H.; Keystone, E. Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: Review of key Phase 2 studies. Int. J. Rheum. Dis., 2016, 19(12), 1216-1225.
[http://dx.doi.org/10.1111/1756-185X.12901] [PMID: 27451980]
[32]
Lamba, M.; Wang, R.; Fletcher, T.; Alvey, C.; Kushner, J.I.V.; Stock, T.C. Extended-release once-daily formulation of tofacitinib: Evaluation of pharmacokinetics compared with immediate-release tofacitinib and impact of food. J. Clin. Pharmacol., 2016, 56(11), 1362-1371.
[http://dx.doi.org/10.1002/jcph.734] [PMID: 26970526]
[33]
El Jammal, T.; Gerfaud-Valentin, M.; Sève, P.; Jamilloux, Y. JAK inhibitors: Perspectives in internal medicine. Rev. Med. Interne, 2019, 40(12), 816-825.
[http://dx.doi.org/10.1016/j.revmed.2019.07.016] [PMID: 31699450]
[34]
Younis, U.S.; Vallorz, E.; Addison, K.J.; Ledford, J.G.; Myrdal, P.B. Preformulation and evaluation of tofacitinib as a therapeutic treatment for asthma. AAPS PharmSciTech, 2019, 20(5), 167.
[http://dx.doi.org/10.1208/s12249-019-1377-0] [PMID: 30993508]
[35]
Al-Salama, Z.T.; Scott, L.J. Baricitinib: A review in rheumatoid arthritis. Drugs, 2018, 78(7), 761-772.
[http://dx.doi.org/10.1007/s40265-018-0908-4] [PMID: 29687421]
[36]
Feist, E.; Burmester, G.R. Small molecules targeting JAKs--a new approach in the treatment of rheumatoid arthritis. Rheumatology, 2013, 52(8), 1352-1357.
[http://dx.doi.org/10.1093/rheumatology/kes417] [PMID: 23378664]
[37]
Yamaoka, K. Janus kinase inhibitors for rheumatoid arthritis. Curr. Opin. Chem. Biol., 2016, 32, 29-33.
[http://dx.doi.org/10.1016/j.cbpa.2016.03.006] [PMID: 26994322]
[38]
Genovese, M.C.; Smolen, J.S.; Takeuchi, T.; Burmester, G.; Brinker, D.; Rooney, T.P.; Zhong, J.; Daojun, M.; Saifan, C.; Cardoso, A.; Issa, M.; Wu, W-S.; Winthrop, K.L. Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: An updated integrated safety analysis. Lancet Rheumatol., 2020, 2(6), e347-e357.
[http://dx.doi.org/10.1016/S2665-9913(20)30032-1]
[39]
Richez, C.; Truchetet, M.E.; Kostine, M.; Schaeverbeke, T.; Bannwarth, B. Efficacy of baricitinib in the treatment of rheumatoid arthritis. Expert Opin. Pharmacother., 2017, 18(13), 1399-1407.
[http://dx.doi.org/10.1080/14656566.2017.1359256] [PMID: 28737053]
[40]
Smolen, J.S.; Genovese, M.C.; Takeuchi, T.; Hyslop, D.L.; Macias, W.L.; Rooney, T.; Chen, L.; Dickson, C.L.; Riddle Camp, J.; Cardillo, T.E.; Ishii, T.; Winthrop, K.L. Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J. Rheumatol., 2019, 46(1), 7-18.
[http://dx.doi.org/10.3899/jrheum.171361] [PMID: 30219772]
[41]
Napolitano, M.; Fabbrocini, G.; Cinelli, E.; Stingeni, L.; Patruno, C. Profile of baricitinib and its potential in the treatment of moderate to severe atopic dermatitis: A short review on the emerging clinical evidence. J. Asthma Allergy, 2020, 13, 89-94.
[http://dx.doi.org/10.2147/JAA.S206387] [PMID: 32099414]
[42]
Honda, S.; Harigai, M. The safety of baricitinib in patients with rheumatoid arthritis. Expert Opin. Drug Saf., 2020, 19(5), 545-551.
[http://dx.doi.org/10.1080/14740338.2020.1743263] [PMID: 32174196]
[43]
Mohamed, M.E.F.; Klünder, B.; Othman, A.A. Clinical pharmacokinetics of upadacitinib: Review of data relevant to the rheumatoid arthritis indication. Clin. Pharmacokinet., 2020, 59(5), 531-544.
[http://dx.doi.org/10.1007/s40262-019-00855-0] [PMID: 31867699]
[44]
Pope, J.; Sawant, R.; Tundia, N.; Du, E.X.; Qi, C.Z.; Song, Y.; Tang, P.; Betts, K.A. Comparative efficacy of JAK inhibitors for moderate-to-severe rheumatoid arthritis: A network meta-analysis. Adv. Ther., 2020, 37(5), 2356-2372.
[http://dx.doi.org/10.1007/s12325-020-01303-3] [PMID: 32297280]
[45]
Cohen, S.B.; van Vollenhoven, R.F.; Winthrop, K.L.; Zerbini, C.A.F.; Tanaka, Y.; Bessette, L.; Zhang, Y.; Khan, N.; Hendrickson, B.; Enejosa, J.V.; Burmester, G.R. Safety profile of upadacitinib in rheumatoid arthritis: Integrated analysis from the SELECT phase III clinical programme. Ann. Rheum. Dis., 2021, 80(3), 304-311.
[http://dx.doi.org/10.1136/annrheumdis-2020-218510] [PMID: 33115760]
[46]
Klünder, B.; Mittapalli, R.K.; Mohamed, M.E.F.; Friedel, A.; Noertersheuser, P.; Othman, A.A. Population pharmacokinetics of upadacitinib using the immediate-release and extended-release formulations in healthy subjects and subjects with rheumatoid arthritis: Analyses of phase I–III clinical trials. Clin. Pharmacokinet., 2019, 58(8), 1045-1058.
[http://dx.doi.org/10.1007/s40262-019-00739-3] [PMID: 30945116]
[47]
El Jammal, T.; Gerfaud-Valentin, M.; Sève, P.; Jamilloux, Y. Inhibition of JAK/STAT signaling in rheumatologic disorders: The expanding spectrum. Joint Bone Spine, 2020, 87(2), 119-129.
[http://dx.doi.org/10.1016/j.jbspin.2019.09.005] [PMID: 31521793]
[48]
Tanaka, Y.; Kavanaugh, A.; Wicklund, J.; McInnes, I.B. Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials. Mod. Rheumatol., 2022, 32(1), 1-11.
[http://dx.doi.org/10.1080/14397595.2021.1902617] [PMID: 33740386]
[49]
T, Virtanen A.; Haikarainen, T.; Raivola, J.; Silvennoinen, O. Selective JAKinibs: Prospects in inflammatory and autoimmune diseases. BioDrugs, 2019, 33(1), 15-32.
[http://dx.doi.org/10.1007/s40259-019-00333-w] [PMID: 30701418]
[50]
Robinson, M.F.; Damjanov, N.; Stamenkovic, B.; Radunovic, G.; Kivitz, A.; Cox, L.; Manukyan, Z.; Banfield, C.; Saunders, M.; Chandra, D.; Vincent, M.S.; Mancuso, J.; Peeva, E.; Beebe, J.S. Efficacy and Safety of PF-06651600 (Ritlecitinib), a novel JAK3/TEC inhibitor, in patients with moderate‐to‐severe rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol., 2020, 72(10), 1621-1631.
[http://dx.doi.org/10.1002/art.41316] [PMID: 32419304]
[51]
Köhler, B.M.; Günther, J.; Kaudewitz, D.; Lorenz, H.M. Current therapeutic options in the treatment of rheumatoid arthritis. J. Clin. Med., 2019, 8(7), 938.
[http://dx.doi.org/10.3390/jcm8070938] [PMID: 31261785]
[52]
Lee, J.S.; Kim, S.H. Dose-dependent pharmacokinetics of tofacitinib in rats: Influence of hepatic and intestinal first-pass metabolism. Pharmaceutics, 2019, 11(7), 318.
[http://dx.doi.org/10.3390/pharmaceutics11070318] [PMID: 31284540]
[53]
Kuriya, B.; Cohen, M.D.; Keystone, E. Baricitinib in rheumatoid arthritis: Evidence-to-date and clinical potential. Ther. Adv. Musculoskelet. Dis., 2017, 9(2), 37-44.
[http://dx.doi.org/10.1177/1759720X16687481] [PMID: 28255337]
[54]
He, Y.; Wong, A.Y.S.; Chan, E.W.; Lau, W.C.Y.; Man, K.K.C.; Chui, C.S.L.; Worsley, A.J.; Wong, I.C.K. Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: A systematic review and meta-analysis. BMC Musculoskelet. Disord., 2013, 14(1), 298.
[http://dx.doi.org/10.1186/1471-2474-14-298] [PMID: 24139404]
[55]
Huang, F.; Luo, Z. Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials. Clin. Rheumatol., 2019, 38(2), 523-534.
[http://dx.doi.org/10.1007/s10067-018-4299-4] [PMID: 30242639]
[56]
Dowty, M.E.; Lin, J.; Ryder, T.F.; Wang, W.; Walker, G.S.; Vaz, A.; Chan, G.L.; Krishnaswami, S.; Prakash, C. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. Drug Metab. Dispos., 2014, 42(4), 759-773.
[http://dx.doi.org/10.1124/dmd.113.054940] [PMID: 24464803]
[57]
Veeravalli, V.; Dash, R.P.; Thomas, J.A.; Babu, R.J.; Madgula, L.M.V.; Srinivas, N.R. Critical assessment of pharmacokinetic drug–drug interaction potential of tofacitinib, baricitinib and upadacitinib, the three approved janus kinase inhibitors for rheumatoid arthritis treatment. Drug Saf., 2020, 43(8), 711-725.
[http://dx.doi.org/10.1007/s40264-020-00938-z] [PMID: 32367507]
[58]
Wang, F.; Sun, L.; Wang, S.; Davis, J.M., III; Matteson, E.L.; Murad, M.H.; Luo, F.; Vassallo, R. Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: A systematic review and meta-analysis. Mayo Clin. Proc., 2020, 95(7), 1404-1419.
[http://dx.doi.org/10.1016/j.mayocp.2020.01.039] [PMID: 32499126]
[59]
Jegatheeswaran, J.; Turk, M.; Pope, J.E. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: A systemic literature review. Immunotherapy, 2019, 11(8), 737-754.
[http://dx.doi.org/10.2217/imt-2018-0178] [PMID: 30955397]
[60]
Bechman, K.; Subesinghe, S.; Norton, S.; Atzeni, F.; Galli, M.; Cope, A.P.; Winthrop, K.L.; Galloway, J.B. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology, 2019, 58(10), 1755-1766.
[http://dx.doi.org/10.1093/rheumatology/kez087] [PMID: 30982883]
[61]
Olivera, P.A.; Lasa, J.S.; Bonovas, S.; Danese, S.; Peyrin-Biroulet, L. Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: A systematic review and meta-analysis. Gastroenterology, 2020, 158(6), 1554-1573.e12.
[http://dx.doi.org/10.1053/j.gastro.2020.01.001] [PMID: 31926171]
[62]
Norman, P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin. Investig. Drugs, 2014, 23(8), 1067-1077.
[http://dx.doi.org/10.1517/13543784.2014.918604] [PMID: 24818516]
[63]
Gadina, M.; Schwartz, D.M.; O’Shea, J.J. Editorial: Decernotinib: A next-generation jakinib. Arthritis Rheumatol., 2016, 68(1), 31-34.
[http://dx.doi.org/10.1002/art.39463] [PMID: 26479275]
[64]
Schroeder, M.A.; Khoury, H.J.; Jagasia, M.; Ali, H.; Schiller, G.J.; Staser, K.; Choi, J.; Gehrs, L.; Arbushites, M.C.; Yan, Y.; Langmuir, P.; Srinivas, N.; Pratta, M.; Perales, M.A.; Chen, Y.B.; Meyers, G.; DiPersio, J.F. A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. Blood Adv., 2020, 4(8), 1656-1669.
[http://dx.doi.org/10.1182/bloodadvances.2019001043] [PMID: 32324888]
[65]
Phillips, T.J.; Forero-Torres, A.; Sher, T.; Diefenbach, C.S.; Johnston, P.; Talpaz, M.; Pulini, J.; Zhou, L.; Scherle, P.; Chen, X.; Barr, P.M. Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma. Blood, 2018, 132(3), 293-306.
[http://dx.doi.org/10.1182/blood-2017-10-812701] [PMID: 29695516]
[66]
Haq, M.; Adnan, G. Ruxolitinib.In: Stat Pearls; Stat Pearls Publishing: Treasure Island, FL, 2021.
[67]
Damsky, W.; King, B.A. JAK inhibitors in dermatology: The promise of a new drug class. J. Am. Acad. Dermatol., 2017, 76(4), 736-744.
[http://dx.doi.org/10.1016/j.jaad.2016.12.005] [PMID: 28139263]
[68]
Abdulrahim, H.; Sharlala, H.; Adebajo, A.O. An evaluation of tofacitinib for the treatment of psoriatic arthritis. Expert Opin. Pharmacother., 2019, 20(16), 1953-1960.
[http://dx.doi.org/10.1080/14656566.2019.1657404] [PMID: 31456440]
[69]
Paik, J.; Deeks, E.D. Tofacitinib: A review in psoriatic arthritis. Drugs, 2019, 79(6), 655-663.
[http://dx.doi.org/10.1007/s40265-019-01091-3] [PMID: 30895473]
[70]
Lee, E.B.; Fleischmann, R.; Hall, S.; Wilkinson, B.; Bradley, J.D.; Gruben, D.; Koncz, T.; Krishnaswami, S.; Wallenstein, G.V.; Zang, C.; Zwillich, S.H.; van Vollenhoven, R.F. Tofacitinib versus methotrexate in rheumatoid arthritis. N. Engl. J. Med., 2014, 370(25), 2377-2386.
[http://dx.doi.org/10.1056/NEJMoa1310476] [PMID: 24941177]
[71]
Dhillon, S. Tofacitinib: A review in rheumatoid arthritis. Drugs, 2017, 77(18), 1987-2001.
[http://dx.doi.org/10.1007/s40265-017-0835-9] [PMID: 29139090]
[72]
Rein, P.; Mueller, R.B. Treatment with biologicals in rheumatoid arthritis: An overview. Rheumatol. Ther., 2017, 4(2), 247-261.
[http://dx.doi.org/10.1007/s40744-017-0073-3] [PMID: 28831712]
[73]
Kaur, K.; Kalra, S.; Kaushal, S. Systematic review of tofacitinib: A new drug for the management of rheumatoid arthritis. Clin. Ther., 2014, 36(7), 1074-1086.
[http://dx.doi.org/10.1016/j.clinthera.2014.06.018] [PMID: 25047498]
[74]
Scott, L.J. Tofacitinib: A review of its use in adult patients with rheumatoid arthritis. Drugs, 2013, 73(8), 857-874.
[http://dx.doi.org/10.1007/s40265-013-0065-8] [PMID: 23716132]
[75]
Harigai, M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology, 2019, 58(S1), i34-i42.
[http://dx.doi.org/10.1093/rheumatology/key287] [PMID: 30806708]
[76]
Ochi, S.; Sonomoto, K.; Nakayamada, S.; Tanaka, Y. Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: From the FIRST Registry. Arthritis Res. Ther., 2022, 24(1), 61.
[http://dx.doi.org/10.1186/s13075-022-02744-7] [PMID: 35232462]
[77]
Song, Y.J.; Cho, S.K.; Kim, H.; Kim, H.W.; Nam, E.; Choi, C.B.; Kim, T.H.; Jun, J.B.; Bae, S.C.; Yoo, D.H.; Sung, Y.K. Risk factors for herpes zoster in Korean patients with rheumatoid arthritis treated with JAK inhibitor: A nested case–control study. RMD Open, 2022, 8(1)e001892
[http://dx.doi.org/10.1136/rmdopen-2021-001892] [PMID: 35091461]
[78]
Janus Kinase (JAK) Inhibitors. Available from: https://creakyjoints.org/education/treatments/jak-inhibitors/
[79]
Cárcamo-Martínez, Á.; Mallon, B.; Anjani, Q.K.; Domínguez-Robles, J.; Utomo, E.; Vora, L.K.; Tekko, I.A.; Larrañeta, E.; Donnelly, R.F. Enhancing intradermal delivery of tofacitinib citrate: Comparison between powder-loaded hollow microneedle arrays and dissolving microneedle arrays. Int. J. Pharm., 2021, 593120152
[http://dx.doi.org/10.1016/j.ijpharm.2020.120152] [PMID: 33301867]
[80]
Scott, I.C.; Hider, S.L.; Scott, D.L. Thromboembolism with Janus kinase (JAK) inhibitors for rheumatoid arthritis: How real is the risk? Drug Saf., 2018, 41(7), 645-653.
[http://dx.doi.org/10.1007/s40264-018-0651-5] [PMID: 29500799]
[81]
Koenders, M.I.; van den Berg, W.B. Novel therapeutic targets in rheumatoid arthritis. Trends Pharmacol. Sci., 2015, 36(4), 189-195.
[http://dx.doi.org/10.1016/j.tips.2015.02.001] [PMID: 25732812]
[82]
Iwata, S.; Tanaka, Y. Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis. Expert Rev. Clin. Immunol., 2016, 12(10), 1047-1057.
[http://dx.doi.org/10.1080/1744666X.2016.1189826] [PMID: 27253519]
[83]
Roongta, R.; Ghosh, A. Managing rheumatoid arthritis during COVID-19. Clin. Rheumatol., 2020, 39(11), 3237-3244.
[http://dx.doi.org/10.1007/s10067-020-05358-z] [PMID: 32892311]
[84]
Semerano, L.; Decker, P.; Clavel, G.; Boissier, M.C. Developments with investigational Janus kinase inhibitors for rheumatoid arthritis. Expert Opin. Investig. Drugs, 2016, 25(12), 1355-1359.
[http://dx.doi.org/10.1080/13543784.2016.1249565] [PMID: 27748152]
[85]
Coates, L.C.; FitzGerald, O.; Helliwell, P.S.; Paul, C. Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same? Semin. Arthritis Rheum., 2016, 46(3), 291-304.
[http://dx.doi.org/10.1016/j.semarthrit.2016.05.012] [PMID: 27388027]
[86]
Nagy, G.; Roodenrijs, N.M.T.; Welsing, P.M.J.; Kedves, M.; Hamar, A.; van der Goes, M.C.; Kent, A.; Bakkers, M.; Pchelnikova, P.; Blaas, E.; Senolt, L.; Szekanecz, Z.; Choy, E.H.; Dougados, M.; Jacobs, J.W.G.; Geenen, R.; Bijlsma, J.W.J.; Zink, A.; Aletaha, D.; Schoneveld, L.; van Riel, P.; Dumas, S.; Prior, Y.; Nikiphorou, E.; Ferraccioli, G.; Schett, G.; Hyrich, K.L.; Mueller-Ladner, U.; Buch, M.H.; McInnes, I.B.; van der Heijde, D.; van Laar, J.M. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann. Rheum. Dis., 2022, 81(1), 20-33.
[http://dx.doi.org/10.1136/annrheumdis-2021-220973] [PMID: 34407926]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy